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Abstract 
Background: Proteinaceous bioactive substances and pharmaceuticals are most conveniently administered orally. 
However, the facing problems are the side effects of proteolytic degradation and denaturation in the gastrointestinal 
tract. In recent years, lactic acid bacteria (LAB) have been verified to be a promising delivery vector for susceptible 
functional proteins and drugs. KiSS-1 peptide, a cancer suppressor, plays a critical role in inhibiting cancer metasta-
sis and its activity has been confirmed by direct administration. However, whether this peptide can be functionally 
expressed in LAB and exert activity on cancer cells, thus providing a potential alternative administration manner in the 
future, has not been demonstrated.
Results: A recombinant Lactococcus lactis strain NZ9000-401-kiss1 harboring a plasmid containing the gene of the 
tumor metastasis-inhibiting peptide KiSS1 was constructed. After optimization of the nisin induction conditions, 
the recombinant strain efficiently secreted KiSS1 with a maximum detectable amount of 27.9 μg/ml in Dulbecco’s 
Modified Eagle medium. The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide and would healing assays, 
respectively, indicated that the secreted KiSS1 peptide remarkably inhibited HT-29 cell proliferation and migration. 
Furthermore, the expressed KiSS1 was shown to induce HT-29 cell morphological changes, apoptosis and reduce the 
expression of matrix metalloproteinase 9 (MMP-9) at both mRNA and protein levels.
Conclusions: A recombinant L. lactis NZ9000-401-kiss1 successfully expressing the human kiss1 was constructed. The 
secreted KiSS1 peptide inhibited human HT-29 cells’ proliferation and migration probably by invoking, or mediating 
the cell-apoptosis pathway and by down regulating MMP-9 expression, respectively. Our results suggest that L. lactis is 
an ideal cell factory for secretory expression of tumor metastasis-inhibiting peptide KiSS1, and the KiSS1-producing L. 
lactis strain may serve as a new tool for cancer therapy in the future.
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Background
Oral administration employing delivery systems like 
hydrogels, nanoparticles, microspheres, and lipid-based 
systems is a convenient way of delivering drugs. However, 
this strategy usually has poor efficiency for bioactive 
macromolecules such as peptides and proteins due to 
the harsh gastrointestinal environment, with proteolysis 
resulting in denaturation and degradation of susceptible 
components [1]. Strategies for the delivery of proteina-
ceous agents have been intensively explored [2–4] to 
reduce the burden of repeat dosages and increased cost 
to improve the therapeutic effect. Potential alternative 
route might be using living microorganisms or other 
improved physically coated delivery vectors [4, 5].
Open Access
Microbial Cell Factories
*Correspondence:  swchen@cau.edu.cn 
1 Beijing Advanced Innovation Center for Food Nutrition and Human 
Health, College of Food Science and Nutritional Engineering, China 
Agricultural University, No. 17 Qinghua East Road, Haidian District, 
Beijing 100083, People’s Republic of China
Full list of author information is available at the end of the article
Page 2 of 11Zhang et al. Microb Cell Fact  (2016) 15:102 
Lactic acid bacteria (LAB) are generally regarded as safe 
for human health. In the last two decades, the feasibility of 
using LAB as functional protein delivery vectors has been 
widely investigated [6]. Lactococcus lactis, a LAB model 
species, has been demonstrated to be a promising candi-
date for the delivery of functional proteins, mainly because 
this bacterium is a noninvasive and nonpathogenic organ-
ism with fewer secretary proteins and extracellular pro-
teases produced [7]. Many different expression systems of 
L. lactis have been developed and used for heterologous 
protein expression [8–10]. The most commonly used sys-
tem is the nisin-controlled gene expression (NICE) sys-
tem, containing the nisin promoter [8]. Some successful 
examples using L. lactis as a functional protein-delivery 
vector have been reported [10–12]. In particular, use of an 
interleukin-10-secreting L. lactis to treat Crohn’s disease 
has passed phase I clinical trials [13], indicating that L. lac-
tis is indeed a safe mucosal vector for functional protein 
delivery. Tumor-targeted reagents, anticancer drugs, and 
non-invasive insulin- and vaccine-delivery systems can be 
developed based on live L. lactis [14, 15].
Nowadays, in cancer research, more attentions have been 
paid on the blockade of the metastatic process at the early 
stage [16]. Therefore, there is growing interest in identify-
ing metastasis suppressor genes, which may be involved in 
the anti-metastatic activity. Kisspeptins (KiSS1) are peptide 
products of the kiss1 gene, which was first identified by Lee 
et  al. [17] in 1996 as a suppressor of tumor metastasis in 
human malignant melanoma cells. Gene kiss1 is predicted 
to encode a 145-amino-acid peptide that can be cleaved 
into smaller peptides, known as kisspeptin-54 (KP54), 
KP14, KP13, and KP10. KiSS1 has been studied in various 
types of cancer and has been suggested to play multiple 
roles in cancer development and in suppression of metas-
tasis, such as thyroid cancer, oesophageal carcinoma, uri-
nary bladder cancer, gastric carcinoma, epithelial ovarian 
cancer, and colorectal cancer [18–23]. These studies pro-
vided numerous experimental and clinical evidences that 
KiSS1 could be a potential molecular target for treatment 
of metastasis during cancer progression.
Some of previous studies used synthetic or purified 
KiSS1 form tissue to investigate the anti-tumor effect 
of KiSS1 on cancer cells [24–27], while others applied 
transfection method (using expression vector containing 
kiss1 gene) to introduce KiSS1 into the tumor cells [28]. 
However, limited information is available with respect to 
the development of new strategies for delivering this pro-
teinaceous anti-tumor molecule for therapeutic purpose 
in the future.
In this study, we evaluated whether L. lactis can be 
used as a cell factory to produce bioactive KiSS1 peptide 
and whether the secreted product has anti-tumor activ-
ity using the human colon cancer HT-29 as a model for 
in vitro experiments. Our results provide foundations for 
future exploitation of recombinant LAB for in vivo deliv-
ery of the proteinaceous agent KiSS1 in cancer therapy.
Results
Cloning and expression of kiss1 in L. lactis NZ9000
The whole kiss1 gene in length of 417 bp was amplified 
from the cDNA of human placenta by PCR and cloned 
into the nisin-induction vector pNZ401 which contained 
the Usp45 signal peptide and LEISSTCDA [29] syn-
thetic propeptide (Fig.  1a). The resulting recombinant 
plasmids pNZ401 and pNZ401-kiss1 were transformed 
into L. lactis NZ9000, respectively. After induction with 
10  ng/ml nisin for 1  h, the total cell protein and the 
secreted protein in the culture supernatant were sepa-
rately extracted. Western blotting assay using anti-KiSS1 
antibody revealed the expected 14.8-kD protein product 
in both the total protein extract and the extracellular 
protein extract from the recombinant strain harboring 
pNZ401-kiss1 (designated L. lactis NZ9000-pNZ401-
kiss1) (Fig.  1b); however, no KiSS1 band was found in 
the parent strain (NZ9000) harboring the empty vector 
pNZ401 (designated L. lactis NZ9000-pNZ401), sug-
gesting that kiss1 was successfully expressed in L. lactis 
NZ9000.
Optimization of expression conditions and detection 
of KiSS1 secretion
To optimize the expression of the recombinant protein, 
different induction time (at the nisin concentration of 
Fig. 1 The expression of KiSS1 in L. lactis NZ9000. a Schematic rep-
resentation of expression cassettes for controlled and targeted KiSS1 
production in L. lactis NZ9000. b KiSS1 expressed in L. lactis NZ9000 
as detected by western blot. SPUSP45 DNA sequence encoding the 
Usp45 signal peptide, LEISS DNA sequence encoding the LEISSTCDA 
synthetic propeptide
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10 ng/ml) was tested. At each induction conditions, the 
amount of protein expressed was determined by indi-
rect competitive enzyme-linked immunosorbent assay 
(ELISA). The results showed that KiSS1 production 
increased to a maximum detectable concentration of 
18.7 μg/ml after 3–5 h induction (Fig. 2), and decreased 
thereafter. Thus the optimal condition for KiSS1 secre-
tion was determined to be induction for 3 h with 10 ng/
ml nisin.
For the cell experiments, conditioned Dulbecco’s 
Modified Eagle medium (DMEM) was used to deter-
mine KiSS1 secretion. The recombinant strain L. lac-
tis NZ9000-pNZ401-kiss1 as well as the control strain 
were cultured to an OD600 of 0.4, and then resuspended 
at different cell densities (5 × 108 and 5 × 109 CFU/ml) 
in DMEM before nisin addition. To determine the secre-
tion of KiSS1, western blotting was performed to detect 
KiSS1 in the DMEM (Fig.  3a) and quantitative analysis 
was performed by indirect competitive ELISA (Fig.  3b). 
The results showed that the level of secreted KiSS1 was 
positively correlated with bacterial cell density; the maxi-
mal detected KiSS1 levels were 19.7 and 27.9 μg/ml in the 
L. lactis NZ9000-pNZ401-kiss1-conditioned DMEM at 
5 × 108 and 5 × 109 CFU/ml cell densities, respectively. 
No corresponding products were found in the control 
strain L. lactis NZ9000-pNZ401 harboring empty vec-
tor. In addition, no detectable leaky expression of KiSS1 
from the L. lactis NZ9000-pNZ401-kiss1 strain was 
observed (Fig.  3a), indicating that the PnisA promoter 
was highly efficient and fully functional for the induc-
tion of KiSS1 expression by nisin. Taken together, these 
results confirmed that KiSS1 is successfully heterogene-
ously expressed in the recombinant L. lactis NZ9000-
pNZ401-kiss1 and effectively secreted into DMEM using 
10 ng/ml nisin.
L.lactis KiSS1 inhibits HT‑29 cell proliferation and migration
To evaluate whether the secreted KiSS1 was biologically 
active, we first tested the inhibition effect of KiSS1 on 
HT-29 cell proliferation using 3-[4,5-dimethylthiazol-
2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. 
The results showed that both the supernatant of DMEM 
conditioned with L. lactis NZ9000 and NZ9000-pNZ401 
strains inhibited HT-29 cell proliferation; however, the 
rate of HT-29-growth inhibition by KiSS1 in recombinant 
L. lactis NZ9000-pNZ401-kiss1-conditioned DMEM was 
2.52-fold (24  h) and 2.24-fold (48  h) higher (P ≤  0.001) 
than that in L. lactis NZ9000-pNZ401-conditioned 
DMEM at those time points (Fig.  4). The total inhibi-
tion of HT-29 cell proliferation reached 54.2 % (24 h) and 
Fig. 2 The concentration of KiSS1 under different induction time
Fig. 3 KiSS1 secreted by L. lactis NZ9000 in DMEM. a Detected by 
western blotting. b Detected by indirect competitive ELISA. Data are 
presented as mean ± SEM of three independent experiments
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69.1 % (48 h) by KiSS1. Thus the L. lactis-secreted KiSS1 
was correctly processed, functionally folded and actively 
involved in inhibition of HT-29 cell proliferation. We fur-
ther investigated the HT-29 cell migration in monolayer 
culture under different treatments (Fig.  5). HT-29 cells 
were firstly seeded on fibronectin-coated 6-well culture 
plates. After 24-h culture, cell monolayers were wounded 
and the culture medium was replaced by DMEM with 
or without KiSS1. After another 24-h culture, the results 
showed that, in the KiSS1-conditioned medium, the 
migration rate of HT-29 cells was only 44.5  % of that 
in KiSS1-negative medium (P  ≤  0.01), indicating that 
the L. lactis- secreted KiSS1 effectively inhibits HT-29 
migration.
KiSS1 induces cell morphological changes, apoptosis and a 
decrease of MMP‑9 expression
The morphological changes of HT-29 cells cultured in L. 
lactis NZ9000-pNZ401-kiss1-conditioned DMEM dis-
played typical features of cell apoptosis/programmed cell 
death, i.e., various degrees of shrinkage, blebbing, aggre-
gation and lack of obvious boundaries (Fig.  6), whereas 
cells growing in only DMEM or in L. lactis NZ9000-
pNZ401-conditioned DMEM developed with clear, regu-
lar boundaries (Fig. 6a–c).
To further confirm KiSS1 induction of cell apopto-
sis, analytical flow cytometry with Annexin V-PI (pro-
pidium iodide) double staining was used to assay the 
changes in HT-29 cells (Fig.  7). The apoptosis-inducing 
effect was observed in HT-29 cells at different cell cycle 
stages, mostly at the late stage of the cell cycle. The 
KiSS1-negative controls L. lactis NZ9000 and L. lac-
tis NZ9000-pNZ401 and the KiSS1-positive L. lactis 
NZ9000-pNZ401-kiss1 all induced constitutive apop-
tosis, at a rate of 13.26, 19.18 and 37.63 % of total cells, 
respectively (Fig.  7a–c). However, the apoptotic rate 
induced by the KiSS1-positive L. lactis NZ9000-pNZ401-
kiss1 was 1.96-fold (P ≤ 0.001) and 2.8-fold (P ≤ 0.001) of 
that by L. lactis NZ9000-pNZ401 and L. lactis NZ9000, 
respectively. These results confirmed that KiSS1 secreted 
by L. lactis has apoptosis-inducing effects on the HT-29 
cell. Therefore, we infer that the inhibition of HT-29 cell 
Fig. 4 KiSS1 inhibits HT-29 cell proliferation. Data are presented 
as mean ± SEM of three independent experiments. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001
Fig. 5 KiSS1 inhibits HT-29 cell migration. a Cell migration under L. lactis NZ9000-pNZ401 and L. lactis NZ9000-pNZ401-kiss1 treatment. b Cell 
migration ratio. Data are presented as mean ± SEM of three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Magnification 100×
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Fig. 6 Photomicrographs of HT-29 cells treated with KiSS1 for 24 h. a Nontreated control. b Cells treated with L. lactis NZ9000-pNZ401. c Cells 
treated with L. lactis NZ9000-pNZ401-kiss1. Red arrow indicates apoptotic cell. Magnification 250×
Fig. 7 Effect of KiSS1 on HT-29 cell apoptosis. a Nontreated control. b Cells treated with L. lactis NZ9000-pNZ401. c Cells treated with L. lactis 
NZ9000-pNZ401-kiss1. d Percentage of apoptotic cells induced by KiSS1. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Quadrant 2 (upper right) and quadrant 
4 (lower right) in panels a, b and c indicate late and early apoptotic cells, respectively
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proliferation by KiSS1 from L. lactis is probably through 
invoking, or mediating the cell-apoptosis pathway.
Previous studies have shown that the expression level 
of matrix metalloproteinase 9 (MMP-9) is important 
for tumor cell invasion, migration and metastasis [29]. 
To examine whether KiSS1 affects MMP-9 expression, 
MMP-9 gene transcription and protein expression in 
HT-29 cells under the different treatments, with or with-
out KiSS1-conditioned medium, were assayed (Fig.  8). 
Both the intensities of MMP-9 mRNA and protein bands 
in the cells treated with L. lactis NZ9000-secreted KiSS1 
were lower than in the other two groups (no treatment 
and L. lactis NZ9000 harboring pNZ401 vector). As 
shown in Fig. 8c, the relative expression level of MMP-9 
protein in the KiSS1 group decreased 3.75-fold com-
pared to L. lactis NZ9000 harboring pNZ401 vector 
(P ≤ 0.001), suggesting that the expression of MMP-9 in 
HT-29 cells was downregulated by the L. lactis NZ9000-
secreted KiSS1, thus exerting the inhibition effects on cell 
proliferation and migration.
KiSS1 downregulates MMP‑9 expression through G‑protein 
coupled receptor 54 (GPR54) and activated ERK‑MAPK 
signaling pathway
It is reported that the downregulation of MMP-9 via 
GPR54 and ERK-MAPK signaling pathway was involved 
in the inhibitory effect of KiSS1 on the migration and 
invasion of cancer cells [30, 31]. To confirm this and to 
investigate the specificity of KiSS-1 action, kisspeptin 234 
(GPR54 inhibitor), a 10-amino acid peptide antagonist 
for the kisspeptin-1/GPR-54 signaling system, was used 
in the inhibition experiments and the expression levels 
of Phosphor-Erk1/2 (ERK-MAPK pathway) and MMP-9 
were evaluated. As shown in Fig. 9, KiSS1 expressed in L. 
lactis NZ9000-kiss1 obviously activated the expression of 
Phosphor-Erk1/2 and reduced the expression of MMP-
9. On the contrary, when the inhibitor, kisspeptin 234, 
was added, the expression of Phosphor-Erk1/2 was sig-
nificantly inhibited while the expression of MMP-9 was 
reversed. These results indicated that KiSS1 expressed in L. 
lactis effectively downregulated the expression of MMP-9 
through the previously reported G-protein coupled recep-
tor 54 and the activated ERK-MAPK signaling pathway.
Discussion
The safety and efficacy of the food-grade microorgan-
ism L. lactis as oral vectors for mucosal delivery has been 
widely confirmed [6, 14]. Bioactive molecules delivered by 
this bacterium for therapeutic purpose (using both in vitro 
and in  vivo models) includes anti-TNFα nanobodies for 
treatment of inflammatory bowel disease (IBD), glucagon 
like peptide-1 (GLP-1) for type 2 diabetes, leptin for body 
weight control, HPV-16 E7 protein for cervical cancer, cata-
lase for IBD/colorectal cancer, among others [14]. In this 
Fig. 8 KiSS1 decreases MMP-9 transcription and expression. a MMP-9 transcription level. b MMP-9 protein level. c Relative MMP-9 protein expres-
sion level
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study, we further verified that L. lactis was an excellent can-
didate as a delivery vector that can be engineered to secrete 
the anti-cancer peptide KiSS1 using the nisin-inducible 
expression system. In addition, it was demonstrated that 
tumor growth can be inhibited by the LAB strain itself [32, 
33] due to the LAB’s ability to produce exopolysaccharides 
[34, 35], which is also an attractive feature for using L. lactis 
to deliver anti-cancer bioactive protein. We also observed 
that, as shown in Figs. 4 and 6, the control groups (L. lactis 
NZ9000 and L. lactis NZ9000-pNZ401) can inhibit HT-29 
proliferation and induce cell apoptosis.
KiSS1 and its receptor KiSS1R have been studied for 
their metastasis-suppressing ability in numerous human 
cancer cells [20, 22, 24]. For example, it is found that high 
expression of KiSS1 can inhibit proliferation and invasion 
of tumor cells via lipofectin transfection of expression 
vector containing full-length KiSS1 complementary DNA 
(cDNA) into the tumor cell [28]. KP10, a short 10-amino 
acid peptide of KiSS1, can also inhibit proliferation and 
migration of tumor cells in vitro and in vivo [25, 36, 37]. 
We therefore hypothesized that expression of biologically 
active KiSS1 would inhibit proliferation and migration of 
different kinds of cancer cells. As an example shown here, 
L. lactis NZ9000 was demonstrated to be a cell factory for 
the secretion of biologically active KiSS1 protein, exerting 
inhibition effects on human colorectal cancer HT-29 cells.
Matrix metalloproteinases (MMPs) play crucial roles in 
invasion, metastasis and regulation of the signaling path-
ways controlling tumor cell growth, survival, invasion, 
inflammation and angiogenesis [38–40]. MMP-9 can 
release factors sequestered in the extracellular matrix, 
including VEGF, TGF-β and FGF-2, and stimulate pro-
liferation and migration of endothelial cells [38, 41]. It is 
evidenced that KiSS-1 can suppress MMP-9 expression 
[42]; we therefore tested whether our expressed pro-
tein had such activity. The results firmly confirmed that 
KiSS1 secreted from our recombinant L. lactis NZ9000-
pNZ401-KiSS1 strain effectively downregulated the 
expression of MMP-9. The reason for this is that KiSS1 is 
known to activate the MAPK pathway via GPR54 signal-
ing, suppressing NFκB binding to the MMP-9 promoter 
and thus downregulating MMP-9 expression [31]. This, 
in turn, reduces the survival rate, inhibits metastasis and 
induces dormancy of cancer cells. Here, by using GPR54 
inhibitor, we further confirmed that KiSS1 expressed in 
L. lactis can effectively downregulate the expression of 
MMP-9 via GPR54 and the ERK-MAPK signaling path-
way. These results were in accordance with previous find-
ings for KiSS1 [43–45], warranting further exploration 
of the effectiveness of KiSS1-secreting L. lactis in vivo at 
inducing apoptosis, and inhibiting cell proliferation and 
metastasis.
Conclusions
The human tumor-metastasis inhibitor protein KiSS1 was 
successfully expressed in L. lactis. The secreted KiSS1 
remarkably inhibited human colonic epithelial HT-29 
cell proliferation and migration mainly by inducing apop-
tosis and inhibiting MMP-9 expression, respectively. To 
our knowledge, this is the first time that the biologically 
active KiSS1 protein was successfully expressed in L. 
lactis and the anti-cancer effects of the secreted protein 
were evaluated. Our study suggests that L. lactis is an 
ideal vector for the secretion expression of anti-cancer 
agent KiSS1, which maybe a promising strategy for can-
cer therapy in the future.
Methods
Bacterial strains and growth conditions
The strains and plasmids used in this study are listed in 
Table  1. L. lactis NZ9000 was cultured in M17 (Difco) 
containing 0.5 % (w/v) glucose at 30 °C without shaking. 
To culture recombinant L. lactis strains, erythromycin 
was added at 5 μg/ml. Escherichia coli was incubated in 
LB medium at 37 °C with shaking at 220 rpm for 16 h.
Gene cloning, plasmid construction, and heterologous 
expression and secretion of KiSS1 by L. lactis NZ9000
The primers used in this study are listed in Table  2. 
Plasmid preparation, restriction endonuclease diges-
tion, DNA ligation and other recombinant DNA tech-
niques were performed according to standard methods 
Fig. 9 The expression of p-Erk1/2 and MMP-9 under different 
conditions (KiSS1 vs. KiSS1 plus GPR54 inhibitor). The expression of 
GAPDH was used as control in each condition. Kisspeptin 234, GPR54 
inhibitor
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[47]. The PCR product of Homo sapiens KiSS-1 metas-
tasis-suppressor cDNA (GenBank accession number 
BC022819.1) was cloned into plasmid pNZ401, result-
ing pNZ401-kiss1. Plasmids pNZ401-kiss1 and empty 
control pNZ401 extracted from E. coli DH5α were both 
transformed into L. lactis NZ9000. For inducible expres-
sion, the recombinant L. lactis NZ9000-pNZ401-kiss1 
and control (NZ9000-pNZ401) transformants were 
grown overnight in glucose-M17 (GM17) medium con-
taining 5 μg/ml erythromycin. A 2 % (v/v) inoculum of 
the L. lactis strains was transferred to fresh GM17 broth 
and grown at 30  °C without shaking to an optical den-
sity at 600  nm (OD600) of 0.4–0.6, and then 10  ng/ml 
nisin (50  IU/ml, Sigma) was added and the culture was 
incubated for 3  h. To prepare conditioned medium for 
cell experiments, DMEM was used for KiSS1 secre-
tion (DMEM-KiSS1 medium). The inoculated NZ9000-
pNZ401-KiSS1 and NZ9000-pNZ401 strains were grown 
to OD600 of 0.4–0.6, harvested and washed twice with 
PBS (pH 7.2) buffer, then suspended in DMEM with-
out fetal calf serum or antibiotics. Nisin (10 ng/ml) was 
added and the mixture was incubated for 3 h. The mix-
ture was centrifuged and the supernatant was collected, 
neutralized with sodium hydroxide and filtered through 
a 0.22-μm membrane as DMEM-KiSS1 conditioned 
media. Fetal calf serum (10 % v/v) was added for incuba-
tion with HT-29 cells.
Western blot analysis and ELISA quantification of KiSS1
The induced recombinant L. lactis was harvested by 
centrifugation at 8000g for 10 min at 4 °C. Pelleted cells 
were washed three times in PBS, resuspended in PBS 
and disrupted by ultrasonicator. The supernatants were 
placed in fresh tubes and mixed with trichloroacetic 
acid at a ratio of 1:9 (v/v), and allowed to precipitate for 
2 h at 4 °C. Then the mixture was centrifuged at 10,000g 
for 15 min at 4 °C. The liquid was discarded and the pel-
let was washed three times in ice-cold acetone. Finally, 
the pellets were air-dried and dissolved in PBS buffer. 
Each protein sample was mixed with 5×  SDS loading 
buffer (250 mM Tris–HCl pH 6.8, 10 % w/v SDS, 0.5 % 
w/v bromophenol blue, 50  % v/v glycerol, 5  % w/v β 
-mercaptoethanol) and separated by 12  % SDS–PAGE, 
and then transferred to a nitrocellulose membrane 
using a semi-dry transmembrane system. Protein bands 
were detected using anti-KiSS1 rabbit monoclonal anti-
body (Santa Cruz Biotechnology). L. lactis NZ9000- 
pNZ401 (harboring empty vector pNZ401) was used as 
a control.
The concentration of the secreted KiSS1 was estimated 
by indirect competitive ELISA. Microtiter plates with 96 
wells were coated with 100  μl antigen per well diluted 
in 50  mmol/l carbonate buffer (pH 9.8) to a concentra-
tion of 10 µg/ml and incubated overnight at 4 °C. Sample 
solutions and standard antigen (KiSS1 protein, Sigma) 
were respectively incubated overnight at 4  °C with an 
equivalent volume of anti-KiSS1 antibody, diluted 1:400 
in 10  mmol/l PBS (pH 7.4) containing 10  g/l bovine 
Table 1 Bacterial strains and plasmids used in this study
Strains/plasmids Relevant characteristics Source or references
Lactococcus lactis NZ9000 MG1363 pepN::nisRK [46] 
L. lactis NZ9000-pNZ401 L. lactis NZ9000 harboring empty vector pNZ401 This study
L. lactis NZ9000-pNZ401-kiss1 L. lactis NZ9000 harboring pNZ401-kiss1 This study
Escherichia coli DH5α Cloning host Takara
E. coli DH5α-pNZ401 E. coli DH5α harboring empty vector pNZ401 Laboratory stock
E. coli DH5α-pNZ401-kiss1 E. coli DH5α harboring pNZ401- kiss1 This study
pNZ401 Emr, inducible expression vector containing the nisA promoter, derivative of pNZ8048 Laboratory stock
pNZ401-kiss1 pNZ401 carrying kiss1 gene This study
Table 2 Primers used in this study
a The added restriction enzyme sites are underlined
b SPP2 includes Usp45 signal peptide and LEISSTCDA synthetic propeptide
c Homo sapiens KiSS-1 metastasis suppressor: gb:BC022819.1 (cDNA clone 
MGC:39258 IMAGE:5443510)
Primer Sequence (5′ → 3′)a Description and location
Primer 1 ATCCATGGGTATGAAAAAAA 
AGATTAT
Upstream of SPP2-F, NcoIb
Primer 2 CATGCATGCTGCGTCACAAG 
TCGACGATA
Downstream of SPP2-R, SphI
Primer 3 CATGCATGCATGAACTCACT 
GGTTTCTT
Upstream of kiss1-F, SphIc
Primer 4 CCCAAGCTTCAGCCCCGCCC 
AGCGCTTC
Downstream of kiss1-R, HindIII
Primer 5 ACCACAGTCCATGCCATCAC Upstream of GAPDH for 
RT-PCR
Primer 6 TCCACCACCCTGTTGCTGTA Downstream of GAPDH for 
RT-PCR
Primer 7 GGT GGA CCG GAT GTT CCC Upstream of MMP-9 for RT-PCR
Primer 8 GCC CAC CTC TCC TCC Downstream of MMP-9 for 
RT-PCR
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serum albumin (BSA) and 1  g/l Tween 20 (PBS-BSA-
T). The plates were washed four times the next day with 
250  μl per well of 10  mmol/l PBS (pH 7.4) containing 
0.5  g/l Tween 20 (PBS-T). After washing the plates, the 
wells were filled with 100 µl PBS-BSA-T per well to block 
residual free binding sites and incubated for 1 h at 37 °C. 
The plates were washed and then 100 µl per well of reac-
tive mixtures of samples or standard antigen and anti-
bodies were added and incubated for 1 h at 37 °C. After 
washing the plates, the wells were filled with 100 µl per 
well horseradish peroxidase-conjugated goat anti-rabbit 
IgG (Santa Cruz Biotechnology), diluted 1:20,000 in PBS-
BSA-T. After incubation for 1 h at 37 °C, the plates were 
washed again and then 100 µl per well of 3,3′,5,5′-tetra-
methylenbenzidine (TMB, Amresco) substrate solution 
was immediately added. The plates were incubated for 
15 min at 37 °C. Finally, 50 µl per well of 2 mol/l H2SO4 
was added to stop the reaction. Absorption was deter-
mined at the dual wavelengths of 450  nm and 630  nm 
by Multiskan MK3 ELISA plate reader (Thermo Lab-
systems). PBS-BSA-T without anti-KiSS1 antibody was 
included as the blank, and PBS-BSA-T without sample 
was the control.
HT‑29 cell culture and assays
Human colonic epithelial HT-29 cells (ATCC HTB 
38) were cultured in DMEM containing 10  % fetal calf 
serum, and 100 U/ml penicillin/streptomycin. Cell pro-
liferation was analyzed by MTT assay. HT-29 cells were 
seeded in 96-well plates at a density of 105 cells per well 
with DMEM containing 10 % fetal calf serum. After 24 h 
incubation, the medium was discarded and changed to 
DMEM-KiSS1 conditioned medium (100  μl per well). 
Cells were treated at 24 and 48 h. Medium was removed 
and then incubated with 100  μl MTT solution (0.5  mg/
ml) for 4  h. The MTT is converted to blue formazan, 
which was then dissolved in 200 μl DMSO and the sam-
ple was read in a Multiskan MK3 plate reader (Thermo 
Labsystems). Absorption was determined at 540 nm. The 
MTT assay is based on the fact that the MTT can be con-
verted into formazan crystals by viable cells, which deter-
mines mitochondrial activity. In cell populations, the 
total mitochondrial activity is related to the number of 
living cells. Therefore, MTT assay can be used to meas-
ure the in vitro inhibition effect of drugs on cell prolifera-
tion [48].
Detection of apoptosis by flow cytometry
HT-29 cells were inoculated at 5 × 105 cells per well in 
6-well plates. After incubation for 12  h, the cells were 
attached to the plates. The medium was then discarded 
and replaced with DMEM-KiSS1 conditioned medium 
(2 ml per well) incubating for 24 h. HT-29 cells cultured 
in DMEM alone and in L. lactis NZ9000-401-conditioned 
DMEM were used as controls. Cells were then treated 
with Annexin V-PI (propidium iodide) cell apoptosis kit 
(Biyuntian Biotech Co. Ltd.). Apoptosis was detected by 
flow cytometry using a FACScan (Becton–Dickinson).
Wound‑healing assay
HT-29 cells were seeded on fibronectin (40  μg/ml)-
coated 6-well culture plates at a density of 106 per well. 
After 24  h culture, cell monolayers were wounded with 
a pipette tip and washed with PBS. The culture medium 
was discarded and replaced with DMEM containing 1 % 
fetal calf serum with or without KiSS1 (27.9 μg/ml, 1 ml 
per well). Cells were grown for 24 h, and those migrating 
toward the wound regions were imaged and counted. The 
detail experimental procedures were performed accord-
ing to previously described protocol [49].
HT‑29 cell RNA and protein extraction
Total RNA from HT-29 cells was isolated using TRIzol 
Reagent (Invitrogen), and then treated with RNase-free 
DNase I (Takara). RNA concentration was determined 
by spectrophotometry at 260 nm. The absence of resid-
ual DNA in the total RNA digested by DNase I was con-
firmed by PCR. Reverse transcription was carried out 
with M-MLV Reverse Transcriptase (Promega) in a 20-μl 
reaction volume containing 150  ng of random prim-
ers and 1 mM dNTP mix (Tiangen Biotech Co. Ltd.) to 
obtain the cDNA for gene-expression assays with specific 
primers (Table 2).
Total protein was isolated from HT-29 cells using cell 
lysis buffer for western blots (Biyuntian Biotech). The 
cells were treated with cell lysis buffer for 30  min, and 
then transferred, using a cell scraper, into a 1.5-ml tube. 
The cells were disrupted by ultrasonication (9  s, two 
times), centrifuged, and the supernatants were subjected 
to western blotting.
Detection of the expression of MMP‑9 and phosphor‑Erk 
(1/2)
To detect the expression of MMP-9 and phosphor-
Erk (1/2), HT-29 cells were separately treated with the 
expressed KiSS1 (L. lactis NZ9000-401-kiss1) and the 
KiSS1 plus kisspeptin 234 (300  nM for 2  h). The kiss-
peptin 234 trifluoroacetate salt, a GPR54 inhibitor, was 
purchased from Santa Cruz Biotechnologies Inc., (Santa 
Cruz, CA, USA). Anti-MMP-9 XP rabbit monoclonal 
antibody (Cell Signaling Technology), phosphor-Erk (1/2) 
MAPK mouse monoclonal antibody and GAPDH mouse 
monoclonal antibody (Biyuntian Biotech) were used for 
detecting the expression of MMP-9, phosphor-Erk (1/2) 
and GAPDH (used as control), respectively, according to 
standard Western blot procedures.
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Statistical analysis
Statistical analyses were performed using unpaired two-
tailed Student’s t test. P values less than 0.05 were con-
sidered to be statistically significant. Data are presented 
as mean  ±  SEM of three independent repeats in each 
experiment. Data were analyzed using the SPSS software 
(Release 17, SPSS Inc., Chicago, IL, USA).
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